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Abstract
Background: Tuberculosis (TB) remains a leading cause of death in much of sub-Saharan Africa despite available
effective treatment. Prompt initiation of TB treatment and access to antiretroviral therapy (ART) remains vital to the
success of TB control. We assessed time to mortality after treatment onset using data from a large treatment centre
in Nigeria.
Methods: We analysed a retrospective cohort of TB patients that commenced treatment between January 2010
and December 2014 in Aminu Kano Teaching Hospital. We estimated mortality rates per person-months at risk
(pm). Cox proportional hazards model was used to determine risk factors for mortality.
Results: Among 1,424 patients with a median age of 36.6 years, 237 patients (16.6%) died after commencing TB
treatment giving a mortality rate of 3.68 per 100 pm of treatment in this cohort. Most deaths occurred soon after
treatment onset with a mortality rate of 37.6 per 100 pm in the 1st week of treatment. Risk factors for death were
being HIV-positive but not on anti-retroviral treatment (ART) (aHR 1.39(1 · 04–1 · 85)), residence outside the city (aHR
3 · 18(2.28–4.45)), previous TB treatment (aHR 3.48(2.54–4.77)), no microbiological confirmation (aHR 4.96(2.69–9.17)),
having both pulmonary and extra-pulmonary TB (aHR 1.45(1.03–2.02), and referral from a non-programme linked
clinic/centre (aHR 3.02(2.01–4.53)).
Conclusions: We attribute early deaths in this relatively young cohort to delay in diagnosis and treatment of TB,
inadequate treatment of drug-resistant TB, and poor ART access. Considerable expansion and improvement in
quality of diagnosis and treatment services for TB and HIV are needed to achieve the sustainable development goal
of reducing TB deaths by 95% by 2035.
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Background
Despite effective treatment being available for over half a
century, tuberculosis (TB) remains a leading cause of
death worldwide [1, 2]. TB deaths have consistently been
used as targets and indicators to measure progress to-
wards control [3, 4]. An estimated 1 · 5 million individ-
uals died of TB in 2014, disproportionately affecting
countries in sub-Saharan Africa and South-East Asia [5].
In high burden settings, contributory factors include
HIV infection (0.4 million deaths), increasing levels of
drug resistance and co-morbidities such as diabetes, and
social deprivation including homelessness, further ampli-
fied by outdated diagnostics, and treatment [6–8].
Recent evidence suggests that TB prevalence and mor-
tality have been under-estimated in many high-burden
countries with revised estimates from Nigeria changing
global figures in 2013 [9]. Nigeria, the most populous
country in Africa, has an estimated population of over
170 million people. Among the identified 22 high bur-
den countries, Nigeria had the highest death rates in
HIV-negative people in 2014 (97 per 100,000) and a high
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HIV-positive TB death rate (44 per 100,000) [5, 10]. Re-
ports indicate that TB prevalence and deaths have been
underestimated and the 2015 TB mortality rates in Nigeria
may even be higher than the 1990 estimates [5, 10, 11].
TB deaths after treatment has been initiated remain
high and occur within the first few months of treatment
[12–16]. Burden of drug-resistant TB is high in Nigeria,
with an estimated 29,000 (16 per 100,000) new cases in
2015 [17]. Treatment and microscopy services are provided
free in 5,728 treatment centres and 1,765 microscopy sites
across the country, though coverage is disproportionately
higher in urban areas [18]. Among an estimated 3.4 million
people living with HIV in Nigeria, less than 800,000 are on
antiretroviral therapy [19].
Although there are studies describing TB treatment
outcomes in Nigeria, [20–27] there is paucity of infor-
mation on mortality in HIV negative and HIV positive
cohorts. Additionally, the Boko Haram insurgency in the
North-eastern part of the country since 2009, has led to
a population of internally displaced persons from com-
munities often with no access to healthcare who may be
at a higher risk of disease and death. For instance, a sur-
vey of multi-drug resistant TB in North-east states af-
fected by this conflict showed a prevalence of up to
35.7% in most affected state (Borno) [28]. Consequently,
in this study we evaluate mortality and factors associated
with time to death in a large treatment centre.
Methods
Study setting
Kano state in Northern Nigeria is one of the most
populous in the country with over 12 million residents
and has the third highest number of TB cases notified to
the National TB programme [18]. Aminu Kano Teaching
Hospital (AKTH), is a large federal government run uni-
versity hospital, established in 1988, which caters for
populations from Kano and neighbouring states. It has a
turnover of about 400,000 out-patients and over 19,000
in-patient admissions reported in 2013.
The AKTH TB-DOTS clinic provides TB screening,
diagnosis and treatment services to both children and
adults. Patients enrolled in the DOTS service come from
a variety of sources and include suspected and confirmed
TB cases, referred from other clinics within the hospital
and other hospitals including private health facilities.
Other services provided are HIV counselling and testing,
contact tracing, and provision of isoniazid-prophylaxis to
children in close contact with active TB cases.
Patients diagnosed with TB receive treatment based on
the existing national guidelines. Prior to 2014, category 1
treatment (CAT 1) was given to new patients which
comprised 2 months of Rifampicin (R), Isoniazid (H),
Pyrazinamide (Z) and Ethambutol (E) followed by
6 months of EH (up to 2012) or 4 months of RH (from
2013); and CAT 2 regimen for re-treatment patients,
comprised 2 months of RHZE and Streptomycin (S),
1 month of RHZE and 5 months of RHE. However, from
2014, the guideline recommended the same regimen
2RHZE and 4RH for both new and re-treatment cases
with the exception of central nervous system TB which
requires longer treatment. Treatment is also occasionally
extended if final investigations such as sputum smear or
X-ray are not available. Guidelines for investigation (in-
cluding a GeneXpert machine in the TB lab), manage-
ment and referral of multi-drug resistant TB became
available from 2014.
TB Treatment is observed by the health worker in the
clinic once weekly during the intensive phase, and once
monthly in the continuation phase. Daily supervision is
undertaken by a designated guardian.
TB/HIV services are co-located and integrated. Pa-
tients with unknown HIV status at enrolment are rou-
tinely counselled and screened for HIV. Patients with
HIV are followed up in the same clinic. Anti-retroviral
treatment (ART) is based on existing National guide-
lines, and eligibility is based largely on clinical staging of
HIV disease and CD4 count. However, for co-infected
patients that are newly diagnosed with HIV or those
diagnosed with TB before commencement of ART,
guidelines recommend commencement of ART irre-
spective of HIV disease stage or CD4 count. Though
only ART status at beginning of TB treatment is usually
recorded in the TB registers.
Study design data sources
Patients 15 years and above enrolled in the clinic for
treatment from January 2010 to December 2014 were in-
cluded in the cohort. Data were collected from a com-
bination of clinic-based sources - patient treatment
cards and TB treatment registers. A treatment card is
opened for each patient upon registration in the clinic
on treatment commencement, and each patient is
assigned a unique identification number. Patient and
treatment information including treatment outcome are
recorded in both.
Information available included: age, gender, residence,
sputum smear status, site of disease, HIV status at treat-
ment onset, previous TB treatment, ART status at treat-
ment onset, date of treatment onset, treatment outcome,
and date of censor. Age was categorised into the follow-
ing bands: 15–24, 25–34, 35–44, 45–54 and ≥65 years.
HIV/ART status was determined from HIV and ART sta-
tus at treatment onset and grouped in to HIV-negative,
HIV-positive on ART, HIV-positive not on ART and Un-
known HIV status. Site of disease was classified in to
pulmonary (disease affecting lungs only), extra-pulmonary
(disease affecting organs other than the lung) and both
(disease affecting the lungs and any other organ) and
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patients were also group into bacteriologically-confirmed
(sputum-smear or culture confirmed) or clinically diag-
nosed (smear-negative and physician-confirmed through
other means). Residential status includes Kano residents
(primarily residing within Kano metropolis) and out-
side Kano.
Subjects entered the cohort on the day treatment com-
menced and remained in the cohort until any one of the
following occurred; i) end of treatment ii) death before
end of treatment iii) loss to follow-up from default or
unknown treatment outcome status. The time between
treatment onset and death was the primary outcome
which included all causes based on the WHO 2013 defi-
nitions for treatment outcome [29].
Statistical analysis
We described numbers and proportions for categorical
variables and means (with standard deviation, SD) or
medians (with interquartile range) for quantitative mea-
sures for all patients. To inform the analyses, follow-up
time was time from treatment commencement to date
of censor which was expanded into person-months (pm)
at risk. Mortality rates over time per 100 pm at risk were
estimated and plotted by time since treatment com-
mencement. Covariate stratum-specific mortality rates
were also determined. Kaplan-Meier analysis and log-
rank tests were used to compare survival curves strati-
fied by previous TB treatment and HIV/ART status. To
estimate hazard ratios (HR) with corresponding 95%
confidence intervals (CI), Cox proportional hazards
modelling was fitted and used to determine risk factors
for mortality. Covariates that were associated with each
outcome measure (adjusting for age) with p < 0 · 2 were
included in the multivariable analysis. Variables were in-
cluded in models if they resulted in >10% change-in-
estimate or a change in log likelihood with p-value < 0 ·
2. Variables that resulted in change in coefficient stand-
ard errors of already included variables by >20% were as-
sumed to be collinear and excluded from the model.
All analyses were done using Stata 14 (Stata Corp,
College Station, TX, USA).
Results
Among 1,484 eligible patients, 1424 (96.0%) were
followed-up for analysis (Fig. 1). More than half of the
patients were men (56.9%) and the mean age was 36.6 ±
SD14.4 years. The study cohort characteristics and treat-
ment outcomes are shown in Table 1. About a quarter
(342) had reported a history of being previously treated
for TB. Out of the 568 (40%) participants that were
HIV positive at treatment onset, only 90 (15.8%) were
on ART. Over two-thirds (936) of the patients had
pulmonary tuberculosis, while 223 (16.1%) had both
pulmonary and extra-pulmonary TB. Common
extrapulmonary sites of TB included abdomen, spine,
CNS, lymph nodes, and pericardium.
Characteristics of the 60 patients that were excluded
from this analysis are shown in Table 2. Their mean age
(SD) was 36.4 ± SD14.0 years, and 27 (45%) were HIV-
positive, while eight (13.3%) had unknown HIV status.
Crude mortality
During a total follow-up time of 6436.2 person-months
in 1,424 patients, 237 participants died.
Overall case fatality was 16.6% and the crude mortality
rate was 3.68 (95% CI – 3.24–4.18) per 100 person-
months of follow-up. Crude mortality rates (per 100
person-months) across different covariates are shown in
Table 3. Mortality was highest in participants aged 45–
54 years and those 65 years or more, although the ma-
jority of deaths occurred among those aged 25–54 years.
Males had a slightly higher crude mortality rate
(4.15:95% CI – 3.53–4.87) than females (3.11:95% CI –
2.53–3.83). Nearly 22% of deaths occurred in HIV posi-
tive individuals, however, HIV-positive patients who
were on ART at treatment onset had the lowest crude
mortality rates (1.52:95% CI – 0.72–3.19).
Kaplan-Maier survival curves show differences in sur-
vival between sub-groups (Fig. 2). When stratified by
previous TB treatment, survival was lower for patients
with previous TB treatment(p < 0.0001). When stratified
by HIV/ART status, survival was lowest among HIV-
infected but not on ART (p = 0.001). Analysis of mortal-
ity from time since treatment onset (Table 4) showed
that most deaths occurred within the 1st week of treat-
ment, with a crude mortality rate of 37.6 (95% CI –
31.4–44.9) per 100 person-months of treatment. Death
rates rapidly declined over treatment period.
Multivariable analysis
After adjusting for age, sex, and other covariates, risk of
death was still markedly higher in the 1st week of treat-
ment and declined steadily over treatment period
Fig. 1 Study participants
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(Table 4). Multivariable analysis (Table 5) showed that,
compared to patients aged 15–24 years, those between
45 and 54 years had over twice the risk of death (aHR
2.37: 95% CI – (1.44–3.92)). Risk factors for death were
being HIV-positive but not on ART (aHR 1.39:(1.04–
1.85)), residence outside the city (aHR 3.18(2.28–4.45)),
previous TB treatment (aHR 3.48(2.54–4.77)), no
microbiological confirmation (aHR 4.96(2.69–9.17)),
having both pulmonary and extra-pulmonary TB (aHR
1.45(1.03–2.02)), and referral from a non-programme
linked clinic/centre (aHR 3.02(2.01–4.53)). Calendar
period also had a strong effect on risk of death in both
univariable and multivariable models, such that patients
enrolled at the later periods (2013 and 2014) had lower
risks of death compared to those enrolled earlier
(2010–2011).
Table 1 Description of study cohort
Variable Frequency Percent
Age group (years)
15–24 260 19.5
25–34 396 30.0
35–44 335 25.1
45–54 185 13.9
55–64 87 6.5
> 65 72 5.4
Missing 93
Gender
Male 81 56.9
Female 614 43.1
Residence
Within Kano 1,014 71.2
Outside Kano 410 28.8
Referral facility
DOTS-linked facility 624 45.7
Non DOTS-linked facility 740 54.3
Missing 60
TB diagnosis
Bacteriological 468 32.9
Clinical 956 67.1
TB site
Pulmonary 936 67.4
Extra-pulmonary 229 16.5
Both 223 16.1
Missing 36
HIV/ART status
HIV- 683 48.0
HIV+ on ART 90 6.3
HIV+ not on ART 478 33.6
Unknown HIV status 173 12.2
Previous TB treatment
No 1,082 76.0
Yes 342 24.0
Year of diagnosis
2010–2011 413 29.0
2012 321 22.5
2013 450 31.6
2014 240 16.9
Treatment outcome
Successful 745 52.3
Lost to follow-up 366 25.7
Died 237 16.6
Failed 33 2.3
Transferred-out 43 3.0
Table 2 Characteristics of 60 patients excluded from analysis
Variable Freq (%)
N = 60
Age group (years)
15–24 15 (25.0)
25–34 13 (21.7)
35–44 16 (26.7)
45–54 7 (11.7)
55–64 6 (10.0)
> 65 3 (5.0)
Gender
Female 27 (45.0)
Male 33 (55.0)
Residence
Within Kano 42 (70.0)
Outside Kano 18 (30.0)
TB diagnosis
Bacteriological 2 (3.3)
Clinical 58 (96.7)
TB site
Pulmonary 29 (82.9)
Extra-pulmonary 5 (14.3)
Both 1 (2.9)
HIV/ART status
HIV- 25 (41.7)
HIV+ on ART 0 (0.0)
HIV+ not on ART 17 (28.3)
Unknown HIV status 8 (13.3)
Previous TB treatment
No 56 (93.3)
Yes 4 (6.7)
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Discussion
This study has identified a high case fatality rate
among a cohort of TB patients on treatment in
Nigeria. The majority of deaths in this young cohort
occur shortly after treatment onset. We have com-
pared mortality across different risk factors. Factors asso-
ciated with mortality included HIV infection without
ART, residence outside the city, extrapulmonary and pul-
monary disease, prior TB treatment, the absence of
microbiological confirmation of TB and periods proximal
to treatment onset.
Deaths among patients on TB treatment reported from
different regions of Nigeria are much lower (<10%) than
figures observed in this study (16.6%), except for some
that involved rural health facilities (13.1%) [30], tertiary
health facility (14.8%) [31], elderly (12.3%) [32] and
MDR-TB (15%) [33]. However, following the Boko
Haram insurgency, Kano state is home to a large
Table 3 Mortality rates across explanatory variables
Variable Number Number of deaths (%) Person-months (pm) Mortality rate per 100 pm (95% CI)
Age group (years)
15–24 260 25 (9 · 6) 1344 · 0 1 · 86 (1 · 26-2 · 75)
25–34 395 60 (15 · 2) 1874 · 8 3 · 20 (2 · 49-4 · 12)
35–44 334 50 (15 · 0) 1512 · 2 3 · 31 (2 · 51-4 · 36)
45–54 185 57 (30 · 8) 650 · 8 8 · 76 (6 · 76-11 · 36)
55–64 85 14 (16 · 5) 344 · 5 4 · 06 (2 · 41-6 · 86)
> 65 72 22 (30 · 6) 251 · 7 8 · 74 (5 · 76-13 · 27)
Gender
Male 810 147 (18 · 2) 3544 · 7 4 · 15 (3 · 53-4 · 87)
Female 614 90 (14 · 7) 2891 · 5 3 · 11 (2 · 53-3 · 83)
Residence
Within Kano 1,014 76 (7 · 5) 5208 · 8 1 · 46 (1 · 17-1 · 83)
Outside Kano 410 161 (39 · 3) 1227 · 4 13 · 12 (11 · 24-15 · 31)
Referral facility
DOTS-linked facility 624 34 (5 · 5) 2470 · 7 1 · 05 (0 · 75-1 · 47)
Non DOTS-linked facility 740 201 (27 · 2) 2907 · 0 6 · 91 (6 · 02-7 · 94)
TB diagnosis
Bacteriological 468 13 (2 · 8) 2819 · 1 0 · 46 (0 · 27-0 · 79)
Clinical 956 224 (23 · 4) 3617 · 1 6 · 19 (5 · 43-7 · 05)
TB site
Pulmonary 936 105 (11 · 2) 4527 · 9 2 · 32 (1 · 92-2 · 81)
Extra-pulmonary 229 36 (15 · 7) 1146 · 3 3 · 14 (2 · 27-4 · 35)
Both 223 95 (42 · 6) 719 · 3 13 · 21 (10 · 80-16 · 15)
HIV/ART status
HIV- 683 111 (16 · 3) 3271 · 4 3 · 39 (2 · 82-4 · 09)
HIV+ not on ART 478 104 (21 · 8) 1895 · 4 5 · 49 (4 · 53-6 · 65)
HIV+ on ART 90 7 (7 · 8) 460 · 4 1 · 52 (0 · 72-3 · 19)
Unknown HIV status 173 15 (8 · 8) 809 · 0 1 · 85 (1 · 12-3 · 08)
Previous TB treatment
No 1.082 93 (8 · 6) 5340 · 9 1 · 74 (1 · 42-2 · 13)
Yes 342 144 (42 · 1) 1095 · 3 13 · 15 (11 · 17-15 · 48)
Year of diagnosis
2010–2011 413 76 (18 · 4) 1721 · 5 4 · 41 (3 · 52-5 · 53)
2012 321 81 (25 · 2) 1319 · 1 6 · 14 (4 · 94-7 · 63)
2013 450 53 (11 · 8) 2195 · 3 2 · 41 (1 · 84-3 · 16)
2014 240 27 (11 · 3) 1200 · 2 2 · 25 (1 · 54-3 · 28)
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number displaced and vulnerable populations that may
also have accounted for high mortality. Case fatality re-
ported from other sub-Saharan Africa ranged between 4
and 9% in HIV-uninfected, lower than our finding and
16–35% among HIV-infected, comparable to our ob-
served 20% in this cohort [34]. Case fatality during treat-
ment from outside Africa were lower, other than in
some Asian countries where the cohorts are much older.
For example, in a population-wide studies in Taipei
Taiwan, case fatality was 17 · 8% for all adults (mean age
65 years) [35] and 25% in another study of elderly per-
sons aged 65 or more years (mean age 80 years) [36],
compared to a mean age of 36.6 years in our study. In
Singapore, a nationwide study found a case fatality of
only 11 · 9%, even though their population was much
older and HIV prevalence was very low (0 · 6%) [37]. In
India, case fatality was also much lower (6%), even
though the age distribution was similar to ours (mean –
36 years) [13] possibly due to a lower HIV prevalence
and better access to care. In South Africa, where burden
of HIV and drug resistant TB are high, case fatality
among platinum miners was 12 · 2% [12].
About half of the deaths occurred within the 1st week
of treatment, and over three-quarters within the first
month. This is higher than what was obtained in Mala-
wian hospital based study, where 40% of deaths occurred
within the 1st month of treatment [38]. Early deaths or
clinical worsening after treatment onset have been associ-
ated with disease progression from additional co-morbid ill-
nesses, drug toxicity and poor adherence [14, 15, 39–43].
The high death rates observed so soon after treatment
onset may be attributable to delays in TB diagnosis
and/or initiation of anti-TB and antiretroviral treat-
ment; severe disease; and undiagnosed drug-resistant
TB or co-morbidities.
Delays could be in health care-seeking, diagnosis,
treatment or a combination of them all [44, 45]. In a re-
view of 45 studies across 17 Asian countries, consult-
ation with a public hospital was associated with lower
risk of treatment delay [46]. A systematic review of diag-
nosis and treatment delays in India showed that use of
Government health care providers was a risk factor for
patient-related delays while use of private health care
providers were associated with health system delays [45].
Reports from sub-Saharan Africa indicate that delay was
associated with prior consultation of traditional healers,
private or rural public facilities [47–49]. Although spu-
tum smear microscopy is provided to patients free by
the National TB programme, additional investigations
for diagnosis of TB such as radiographs and histology,
and other co-morbidities such as diabetes have to be
paid for by the patient and may also contribute to delays
and disease progression [50–53]. In a study of platinum
miners in South Africa, although high death rates were
also observed in the first month of treatment irrespect-
ive of HIV/ART status and previous treatment, death
rates were still lower than present study. However, the
miners were covered by a free comprehensive medical
care including HIV care, reducing the likelihood of diag-
nostic and treatment delays and possibly improving early
likelihood of detecting and managing co-existing condi-
tions. The majority of treatment services in Nigeria are
provided by lower cadre health workers at the primary
care level, with limited capacity for diagnosis of sputum-
Fig. 2 Kaplan-Maier curves showing survival by previous TB treatment and by HIV/ART status among study cohort
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negative and extra-pulmonary TB. This may have wors-
ened diagnostic delay. Although the literature suggests
that access to public hospitals lowers the risk of delay, a
large tertiary hospital may represent a different experi-
ence within the TB programme due to the extreme of
spectrum of disease. It is therefore possible that early
deaths in this cohort are reflective of more severe
disease
Decrease in mortality rates we observed over calendar
period could be reflective of changes in treatment pol-
icies which include switch from 8 months (2RHZE/6EH)
to 6 months (2RHZE/4RH) treatment regimen; use of
same regimen for re-treatment cases; revision of CD4
cell count threshold for ART initiation; and introduction
of drug-susceptibility testing. This decrease in mortality
could also be as a result of maturity of the DOTS
programme within the hospital and country at large, as
such delays in diagnosis and treatment may have re-
duced over time; and detection and management of
drug-resistant TB may have improved.
Residing outside Kano city was also associated with in-
creased mortality. Distance from health centre, coexisting
untreated or undiagnosed co-morbid chronic illnesses, un-
availability of health/treatment centres at place of residence,
poor access to ART, and shortage or interrupted supply of
drugs can also contribute to deaths [46, 54, 55]. Addition-
ally, rural areas have fewer TB treatment and ART services
further decreasing access. Delayed treatment initiation has
been shown to be associated with increased periods of in-
fectiousness, disease severity, treatment failure and mortal-
ity [56]. Poor treatment outcomes may reflect socio-
economic conditions including poor awareness and rural
residence which influence access to overall health care [45,
46, 57]. Poor health access may also indicate unrecog-
nised co-morbidities, which can increase risk of death.
About a quarter of the cases were on TB re-treatment,
therefore, it is possible that previous failed treatment
and drug-resistant TB contributed to the poor outcomes
[58, 59]. There were no guidelines or protocol for man-
agement of drug resistant TB in the country during the
initial period covered by this study, and empirical treat-
ment with 1st line anti-tuberculous agents was recom-
mended. A study in AKTH, Kano reported MDR-TB
prevalence of 10.6% [60]. Applying this figure to our co-
hort implies that inadequate treatment of drug-resistant
TB may have increased risk of mortality.
Consistent with previous reports, higher mortality risk
was observed among HIV-infected patients not on ART,
while those who were already on ART when TB treat-
ment was started did not have any excess mortality risk
[61]. Though some studies have shown higher mortality
risk among TB/HIV co-infected soon after initiating
ART, use of ART for at least 6 months has been shown
to reduce mortality [62, 63]. Integrated ART at time of
TB treatment initiation has been shown to reduce mor-
tality [61, 64–66]. The integration of TB-HIV services in
this centre with active clinical screening for TB, could
have resulted in early diagnosis and timely TB treatment
among patients already enrolled in the HIV clinic [67].
Our findings indicate that only 15.8% of HIV-infected
were on ART at the time of TB treatment. This figure
however does not take into account patients who may
receive ART during TB treatment, as well as duration of
ART treatment, CD4 count and HIV disease stage be-
cause these were not updated in the clinic registers. This
may have resulted in under-estimation of the effect of
ART. The observed effect of HIV on risk of death over
time was lower than in other studies across sub-Saharan
Africa [12, 20, 65, 68].
Misdiagnosis of other diseases, especially among HIV-
infected persons as smear-negative or extrapulmonary TB
may partly explain the high mortality rates observed in
clinically-diagnosed patients [44, 69, 70]. For instance, a
study in South Africa found a strong association between
certainty of diagnosis and mortality [12]. Though studies
have shown that autopsy-confirmed causes of deaths at-
tributed to TB are lower than those clinically diagnosed,
autopsies performed on patients whose deaths had been
attributed to other causes have also shown a substantial
proportion of missed TB cases [12, 65, 71, 72].
Table 4 Mortality from time since treatment commencement
Time since treatment
onset
Number of
deaths
Proportionate
mortality (%)
Person-months Mortality rate per
100 pm (95%CI)
Crude HR
(95% CI)
Adjusted HR
(95% CI)a
1st week 120 50 · 6 319 · 3 37 · 6 (31 · 4-44 · 9) 1 1
2nd week 32 13 · 5 265 · 9 12 · 0 (8 · 5-17 · 0) 0 · 34 (0 · 23-0 · 53) 0 · 49 (0 · 31-0 · 78)
3rd week 23 9 · 7 253 · 2 9 · 1 (6 · 0-13 · 7) 0 · 31 (0 · 19-0 · 49) 0 · 57 (0 · 34-0 · 96)
4th week 13 5 · 5 245 · 9 5 · 3 (3 · 1-9 · 1) 0 · 18 (0 · 10-0 · 32) 0 · 31 (0 · 17-0 · 60)
2nd month 21 8 · 9 936 · 8 2 · 2 (1 · 5-3 · 4) 0 · 08 (0 · 05-0 · 12) 0 · 18 (0 · 10-0 · 30)
3rd month 12 5 · 1 885 · 2 1 · 4 (0 · 8-2 · 4) 0 · 04 (0 · 02-0 · 08) 0 · 13 (0 · 07-0 · 26)
4th month+ 16 6 · 7 3530 · 0 0 · 5 (0 · 3-0 · 7) 0 · 01 (0 · 06-0 · 02) 0 · 05 (0 · 03-0 · 08)
aAdjusted for age, gender, residence, calendar period, HIV/ART status, previous TB treatment, TB site, referring source, and diagnosis
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The major strengths of this study include the availabil-
ity of information allowing time to event analysis which
is usually lacking from programme-level data. Findings
should be interpreted in light of a number of limitations.
First, some deaths in this study may not be TB deaths
and would be more appropriately grouped as deaths dur-
ing TB treatment. Thus, we may have over-estimated TB
mortality. Conversely, we might have underestimated
the overall mortality in this population as many deaths
will likely occur before contact with the health system or
the TB programme. Second, although, patients or their
next of kin are usually contacted on reasons for default,
a number of patients who had been lost to follow-up
may have died at home [73]. This may have further
under-estimated mortality. Additionally, death rates
among the 60 patients excluded may be different, and
Table 5 Univariable and multivariable analyses of risk factors for mortalitya
Variable Crude HR (95% CI) P value Adjusted HR (95% CI) p value
Age group (years)
15–24 1 1
25–34 1 · 62 (1 · 01–2 · 58) 1 · 18 (0 · 73–1 · 89)
35–44 1 · 57 (0 · 97–2 · 53) 1 · 07 (0 · 65–1 · 77)
45–54 3 · 79 (2 · 37–6 · 07) 2 · 37 (1 · 44–3 · 92)
55–64 1 · 85 (0 · 96–3 · 57) 1 · 43 (0 · 73–2 · 80)
> 65 3 · 60 (2 · 03–6 · 38) <0 · 001 1 · 64 (0 · 90–2 · 99) 0.001
Gender
Female 1 0 · 06 1
Male 1 · 28 (0 · 99–1 · 67) 0 · 94 (0 · 71–1 · 25) 0 · 68
Residence
Within Kano 1 1
Outside Kano 6. · 74 (5 · 13–8 · 86) <0 · 001 3 · 18 (2 · 28–4 · 45) <0 · 001
Referral facility
DOTS-linked facility 1 1
Non DOTS-linked facility 5 · 85 (4 · 07–8 · 42) <0 · 001 3 · 02 (2 · 01–4 · 53) <0 · 001
TB diagnosis
Bacteriological 1 1
Clinical 10 · 72 (6 · 12–18 · 76) <0 · 001 4 · 96 (2 · 69–9 · 17) <0 · 001
TB site
Pulmonary 1 1
Extra-pulmonary 1 · 46 (1 · 00–2 · 14) 1 · 08 (0 · 72–1 · 63)
Both 4 · 86 (3 · 68–6 · 42) <0 · 001 1 · 45 (1 · 03–2 · 02) 0 · 09
HIV/ART status
HIV- 1 1
HIV+ on ART 0 · 43 (0 · 21–0 · 92) 1 · 51 (0 · 60–3 · 78)
HIV+ not on ART 1 · 42 (1 · 09–1 · 86) 1 · 39 (1 · 04–1 · 85)
Unknown HIV status 0 · 54 (0 · 32–0 · 93) <0 · 001 0 · 77 (0 · 44–1 · 33) 0 · 05
Previous TB treatment
No 1 1
Yes 6 · 43 (4 · 95–8 · 35) <0 · 001 3 · 48 (2 · 54–4 · 77) <0 · 001
Year of diagnosis
2010–2011 1 1
2012 1 · 17 (0 · 86–1 · 60) 1 · 10 (0 · 78–1 · 56)
2013 0 · 48 (0 · 36–0 · 68) 0 · 47 (0 · 32–0 · 69)
2014 0 · 45 (0 · 29–0 · 70) <0 · 001 0 · 45 (0 · 27–0 · 74) <0 · 001
aAdjusted for all variables in the table
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this may have resulted in either under- or over-estimation
of mortality in this cohort. Third, our findings are from a
single treatment centre, therefore, generalisability may be
somewhat limited. However, we believe that our findings
represent the experience of many treatment centres within
tertiary-level health facilities in the country which tend to
see more of severe disease. Fourth, due to the retrospective
nature of this study, we could not account for the effect of
other co-morbidities such as diabetes on the risk of death
as this information is not recorded in the clinic registers.
Conclusion
The high TB mortality observed in a tertiary health
centre may reflect marked delays in diagnosis; poor ac-
cess to care among vulnerable populations; and unrecog-
nised co-existing morbidities. Data from our high-TB
burden low-resource setting illustrates the difficulties re-
lated to diagnosis and treatment of smear negative and
extrapulmonary TB, low ART coverage, poor access to
comprehensive healthcare and the limitations of passive
case-finding. TB programmes in Africa have focused on
passively detecting and treating smear-positive disease
despite evidence of increasing burden of smear-negative
TB including HIV-related TB [34]. To attain the End TB
strategy’s target of zero deaths and suffering from TB,
aggressive strategies need to be employed to actively find
and promptly treat all cases; and make TB care more
comprehensive in order to recognise and adequately
manage other co-morbidities. Wider access to ARTamong
HIV infected persons will also be critical to the TB and
HIV control effort. Considering the limitations of the his-
torical nature of this study, future prospective studies
should aim to differentiate deaths due to TB from coinci-
dental deaths from other causes to adequately define TB
burden; and identify co-morbidities and their contribution
to risk of death among patients with TB.
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